LNTH vs PFE: fair value comparison
Lantheus Holdings, Inc. and Pfizer Inc. · Updated 2026-08-31
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, PFE currently sits closer to the top of our discount ranking. LNTH carries the stronger quality grade.
| LNTH | PFE | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $101.19 | $27.96 |
| 12-month range | $51.63–$108.96 | $24.23–$28.55 |
| Sector rank | #102 of 113 Healthcare | #100 of 113 Healthcare |
| Quality grade | A | F |
| Momentum grade | A | A |
| Leverage | Moderate | Moderate |
| Margin trend | Contracting | Expanding |
| Revenue growth | Strong | Declining |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | — |
| DCF cross-check | Fairly Valued | Undervalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: LNTH fair value analysis · PFE fair value analysis